Yoonho Nam1, Sung-Min Gho2, Dong-Hyun Kim2, Eung Yeop Kim3, Jongho Lee4. 1. Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. 2. Department of Electrical and Electronic Engineering, Yonsei University, Seoul, Korea. 3. Department of Radiology, Gachon University Gil Medical Center, Incheon, Korea. 4. Laboratory for Imaging Science and Technology, Department of Electrical and Computer Engineering, Seoul National University, Seoul, Korea.
Abstract
PURPOSE: To enhance the visibility of nigrosome 1 in substantia nigra, which has recently been suggested as an imaging biomarker for Parkinson's disease (PD) at 3T magnetic resonance imaging (MRI). MATERIALS AND METHODS: The substantia nigra structure was visualized at 3T MRI using multiecho susceptibility map-weighted imaging (SMWI) in 15 healthy volunteers and 6 patients with Parkinson's disease (PD). The visibility of nigrosome 1 was further enhanced by acquiring data in an oblique-coronal imaging plane at a high spatial resolution (0.5 × 0.5 × 1.0 mm3 ). To compare the visibility, the contrast-to-noise ratios (CNR) of the nigrosome 1 structure relative to the neighboring substantia nigra structure were evaluated in the SMWI and other conventional susceptibility contrast images (magnitude, frequency, quantitative susceptibility map [QSM] and susceptibility-weighted image). RESULTS: In healthy volunteers, the CNRs of the nigrosome 1 structure were 1.04 ± 0.38, 0.84 ± 0.32, 1.04 ± 0.40, 0.86 ± 0.41, and 1.45 ± 0.48 for magnitude, frequency, quantitative susceptibility map, susceptibility-weighted image, and SMWI, respectively. Compared to conventional susceptibility contrast images, the SMWI method significantly improved the CNR of nigrosome 1 (P = 0.014 for magnitude, P = 0.030 for QSM, and P < 0.001 for frequency and SWI, respectively). The magnetic susceptibility difference between nigrosome 1 and neighboring substantia nigra structures was 0.037 ± 0.016 ppm (measured in QSM, P < 0.001) in healthy volunteers. In the PD patients, the visibility of the nigrosome 1 structures was reduced. CONCLUSION: The SMWI method enhances the visibility of nigrosome 1 structures at 3T MRI when compared to conventional susceptibility contrast images. LEVEL OF EVIDENCE: 3 Technical Efficacy: Stage 2 J. MAGN. RESON. IMAGING 2017;46:528-536.
PURPOSE: To enhance the visibility of nigrosome 1 in substantia nigra, which has recently been suggested as an imaging biomarker for Parkinson's disease (PD) at 3T magnetic resonance imaging (MRI). MATERIALS AND METHODS: The substantia nigra structure was visualized at 3T MRI using multiecho susceptibility map-weighted imaging (SMWI) in 15 healthy volunteers and 6 patients with Parkinson's disease (PD). The visibility of nigrosome 1 was further enhanced by acquiring data in an oblique-coronal imaging plane at a high spatial resolution (0.5 × 0.5 × 1.0 mm3 ). To compare the visibility, the contrast-to-noise ratios (CNR) of the nigrosome 1 structure relative to the neighboring substantia nigra structure were evaluated in the SMWI and other conventional susceptibility contrast images (magnitude, frequency, quantitative susceptibility map [QSM] and susceptibility-weighted image). RESULTS: In healthy volunteers, the CNRs of the nigrosome 1 structure were 1.04 ± 0.38, 0.84 ± 0.32, 1.04 ± 0.40, 0.86 ± 0.41, and 1.45 ± 0.48 for magnitude, frequency, quantitative susceptibility map, susceptibility-weighted image, and SMWI, respectively. Compared to conventional susceptibility contrast images, the SMWI method significantly improved the CNR of nigrosome 1 (P = 0.014 for magnitude, P = 0.030 for QSM, and P < 0.001 for frequency and SWI, respectively). The magnetic susceptibility difference between nigrosome 1 and neighboring substantia nigra structures was 0.037 ± 0.016 ppm (measured in QSM, P < 0.001) in healthy volunteers. In the PDpatients, the visibility of the nigrosome 1 structures was reduced. CONCLUSION: The SMWI method enhances the visibility of nigrosome 1 structures at 3T MRI when compared to conventional susceptibility contrast images. LEVEL OF EVIDENCE: 3 Technical Efficacy: Stage 2 J. MAGN. RESON. IMAGING 2017;46:528-536.
Authors: N Arai; H Kan; M Ogawa; Y Uchida; M Takizawa; K Omori; T Miyati; H Kasai; H Kunitomo; Y Shibamoto Journal: AJNR Am J Neuroradiol Date: 2019-12-05 Impact factor: 3.825
Authors: Manuel A Schmidt; Tobias Engelhorn; Franz Marxreiter; Juergen Winkler; Stefan Lang; Stephan Kloska; Philipp Goelitz; Arnd Doerfler Journal: BMC Neurol Date: 2017-10-26 Impact factor: 2.474